Locking blood sugar disease with an interleukin therapy: Interleukin(IL-15)-based therapy for TIIDM: IL-15 increases the expression of IGF1R, INSR, and IRS2, and promotes an insulin-sensitized state, via up-regulation of  its target gene Lin28, 1/May/2018, 10.33 pm